ALISO VIEJO, Calif.,
Jan. 10, 2014 /PRNewswire/
-- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) Avanir
announced that on January 7, 2014,
the Company approved the grant of stock options to new employees to
purchase a total of 249,800 shares of common stock in the
aggregate. The stock options were granted as inducements material
to the new employees entering into employment with Avanir, as
permitted under NASDAQ Listing Rule 5635(c)(4).
(Logo:
http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)
Avanir granted to seven new employees an option to purchase
shares of Avanir's common stock with an exercise price equal to
$3.28, the closing price per share of
Avanir's common stock as reported by NASDAQ on January 7, 2014, the date of grant. Each of the
options will vest with respect to one-quarter of the underlying
shares on the first anniversary of the grant date and then with
respect to the remaining shares quarterly thereafter over the
following three years, assuming in each case the employee remains
continuously employed by Avanir.
About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused
on bringing innovative medicines to patients with central nervous
system disorders of high unmet medical need. As part of our
commitment, we have extensively invested in our pipeline and are
dedicated to advancing medicines that can substantially improve the
lives of patients and their loved ones. For more information about
Avanir, please visit www.avanir.com.
AVANIR® is a trademark or registered trademark of
Avanir Pharmaceuticals, Inc. in the
United States and other countries.
©2014 Avanir Pharmaceuticals, Inc. All Rights Reserved.
Forward Looking Statements
Except for the historical information contained herein, the
matters set forth in this press release, including statements
regarding Avanir's plans, potential opportunities, financial or
other expectations, projections, goals objectives, milestones,
strategies, market growth, timelines, legal matters, product
pipeline, clinical studies, product development and the potential
benefits of its commercialized products and products under
development are forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are subject to
risks and uncertainties that may cause actual results to differ
materially, including the risks and uncertainties associated with
Avanir's operating performance and financial position, the market
demand for and acceptance of Avanir's products domestically and
internationally, research, development and commercialization of new
products domestically and internationally, obtaining additional
indications, obtaining and maintaining regulatory approvals
domestically and internationally, and other risks detailed from
time to time in the Company's most recent Annual Report on Form
10-K and other documents subsequently filed with or furnished to
the Securities and Exchange Commission. These forward-looking
statements are based on current information that may change and you
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
All forward-looking statements are qualified in their entirety by
this cautionary statement, and the Company undertakes no obligation
to revise or update any forward-looking statement to reflect events
or circumstances after the issuance of this press release.
Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com
+1 (949) 389-6700
SOURCE Avanir Pharmaceuticals, Inc.